Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Expenses (2023 - 2026)

Mereo BioPharma has reported Operating Expenses over the past 4 years, most recently at $8.8 million for Q1 2026.

  • Quarterly Operating Expenses fell 21.75% to $8.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38.3 million through Mar 2026, down 21.22% year-over-year, with the annual reading at $40.8 million for FY2025, 13.91% down from the prior year.
  • Operating Expenses was $8.8 million for Q1 2026 at Mereo BioPharma, up from $8.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $15.3 million in Q4 2024 and troughed at $6.4 million in Q2 2023.
  • The 4-year median for Operating Expenses is $9.9 million (2024), against an average of $10.2 million.
  • Year-over-year, Operating Expenses skyrocketed 100.81% in 2024 and then tumbled 45.07% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $8.4 million in 2023, then soared by 81.82% to $15.3 million in 2024, then plummeted by 45.07% to $8.4 million in 2025, then increased by 4.48% to $8.8 million in 2026.
  • Per Business Quant, the three most recent readings for MREO's Operating Expenses are $8.8 million (Q1 2026), $8.4 million (Q4 2025), and $10.3 million (Q3 2025).